Publications by authors named "Lisa E Davis"

Claim this Profile
F
Fixed, Systematically Formed versus Continuously Changing Random Team Assignments and Outcomes in a Therapeutics Course.
Ashley M Campbell, Prince Bosiako Antwi, Lisa E Davis, Terri L Warholak

Am J Pharm Educ· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed Versus Body-Sized-Based Dosing of Monoclonal Antibodies.
Brian L Erstad, Lisa E Davis

Ann Pharmacother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Rybak et al.
David E Nix, Lisa E Davis, Kathryn R Matthias

Am J Health Syst Pharm· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Study of Aspirin and Zileuton on Biomarkers of Tobacco-Related Carcinogenesis in Current Smokers.
Linda L Garland, José Guillen-Rodriguez, Chiu-Hsieh Hsu, Lisa E Davis, Eva Szabo

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The relationship of vancomycin 24-hour AUC and trough concentration.
David E Nix, Lisa E Davis, Kathryn R Matthias

Am J Health Syst Pharm· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Literature Review of the Prognostic and Predictive Value of PIK3CA Mutations in HR/HER2 Metastatic Breast Cancer.
Lea E Mollon, Elizabeth J Anderson, Joni L Dean, Terri L Warholak, Ayal Aizer, Lisa E Davis

Clin Breast Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Systematic Review of the Prevalence and Diagnostic Workup of PIK3CA Mutations in HR+/HER2- Metastatic Breast Cancer.
Elizabeth J Anderson, Lea E Mollon, Joni L Dean, Terri L Warholak, Ayal Aizer, Lisa E Davis

Int J Breast Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Intermittent Versus Continuous Low-Dose Aspirin on Nasal Epithelium Gene Expression in Current Smokers: A Randomized, Double-Blinded Trial.
Linda L Garland, José Guillen-Rodriguez, Chiu-Hsieh Hsu, Michael Yozwiak, Hao Helen Zhang, Lisa E Davis

Cancer Prev Res (Phila)· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.
Lisa E Davis, Lauren A Nicholls, Hani M Babiker, Joy Liau, Daruka Mahadevan

Cancer Immunol Res· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma.
Naomi B Haas, Leonard J Appleman, Mark Stein, Maryann Redlinger, Melissa Wilks, Lisa E Davis

Clin Cancer Res· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The evolution of biomarkers to guide the treatment of metastatic colorectal cancer.
Lisa E Davis

Am J Manag Care· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma.
Dan T Vogl, Edward A Stadtmauer, Kay-See Tan, Daniel F Heitjan, Lisa E Davis

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors.
Devalingam Mahalingam, Monica Mita, John Sarantopoulos, Leslie Wood, Ravi K Amaravadi, Lisa E Davis

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma.
Reshma Rangwala, Yunyoung C Chang, Janice Hu, Kenneth M Algazy, Tracey L Evans, Lisa E Davis

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma.
Reshma Rangwala, Robert Leone, Yunyoung C Chang, Leslie A Fecher, Lynn M Schuchter, Lisa E Davis

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme.
Myrna R Rosenfeld, Xiaobu Ye, Jeffrey G Supko, Serena Desideri, Stuart A Grossman, Lisa E Davis

Autophagy· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiency.
Quentin McAfee, Zhihui Zhang, Arabinda Samanta, Samuel M Levi, Xiao-Hong Ma, Lisa E Davis

Proc Natl Acad Sci U S A· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zoledronic acid: a new parenteral bisphosphonate.
Edward C Li, Lisa E Davis

Clin Ther· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis